Synomis, Inc. — SEC Form D Filing

Synomis, Inc. filed an SEC Form D on October 30, 2026, reporting $30K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 30, 2026
Amount reported
$30K
Round stage
Pre-seed, given the small initial capital raise of $30,000 to cover early entity formation and initial proof-of-concept work.
Industry
Biotechnology
Website
https://www.synomis.com

What the company does

Exemption: Rule 506(b). Incorporated: TENNESSEE

Problem

Complex biological targets require novel targeted therapeutic platforms to address high unmet medical needs in patient populations.

Solution

Synomis develops novel biopharmaceutical therapeutics and early-stage biotechnology solutions to treat complex human diseases.

Why now

Recent advancements in genomic sequencing and molecular biology allow early-stage biotechnology startups to validate scientific hypotheses with minimal initial seed capital.

Source: SEC EDGAR Form D filing